PAPER Park J, Im JJ, Song IU, Kang Y
PAPER Yi SH, Suk SH
Letter to the Editor: Relationship Between Neuropsychiatric Symptoms and Activities of Daily Living in Alzheimer Disease.Ann Geriatr Med Res. 2018 Mar;22(1):49-50. Epub 2018 Mar 31 PubMed: 32743246
PAPER Glynn K, O'Callaghan M, Hannigan O, Bruce I, Gibb M, Coen R, Green E, Lawlor B, Robinson D
Clinical utility of mild cognitive impairment subtypes and number of impaired cognitive domains at predicting progression to dementia: A twenty-year retrospective study.Int J Geriatr Psychiatry. 2020 Aug 3; PubMed: 32748438
PAPER Zeng Q, Shen J, Chen K, Zhou J, Liao Q, Lu K, Yuan J, Bi F32747678
PAPER Alruwaili AR, Pannek K, Henderson RD, Gray M, Kurniawan ND, McCombe PA
Serial MRI studies over 12 months using manual and atlas-based region of interest in patients with amyotrophic lateral sclerosis.BMC Med Imaging. 2020 Aug 3;20(1):90. PubMed: 32746800
PAPER Thal DR, Ronisz A, Tousseyn T, Upadhaya AR, Balakrishnan K, Vandenberghe R, Vandenbulcke M, von Arnim CA, Otto M, Beach TG, Lilja J, Heurling K, Chakrabarty A, Ismail A, Buckley C, Smith AP, Kumar S, Farrar G, Walter J
Correction to: Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.Acta Neuropathol Commun. 2020 Aug 3;8(1):121. PubMed: 32746942
PAPER Romagnolo A, Balestrino R, Imbalzano G, Ciccone G, Riccardini F, Artusi CA, Bozzali M, Ferrero B, Montalenti E, Montanaro E, Rizzone MG, Vaula G, Zibetti M, Lopiano L32749601
PAPER Hoffmann TJ, Theusch E, Haldar T, Ranatunga DK, Jorgenson E, Medina MW, Kvale MN, Kwok PY, Schaefer C, Krauss RM, Iribarren C, Risch N29507422
PAPER Wojcik GL, Graff M, Nishimura KK, Tao R, Haessler J, Gignoux CR, Highland HM, Patel YM, Sorokin EP, Avery CL, Belbin GM, Bien SA, Cheng I, Cullina S, Hodonsky CJ, Hu Y, Huckins LM, Jeff J, Justice AE, Kocarnik JM, Lim U, Lin BM, Lu Y, Nelson SC, Park SL, Poisner H, Preuss MH, Richard MA, Schurmann C, Setiawan VW, Sockell A, Vahi K, Verbanck M, Vishnu A, Walker RW, Young KL, Zubair N, Acuña-Alonso V, Ambite JL, Barnes KC, Boerwinkle E, Bottinger EP, Bustamante CD, Caberto C, Canizales-Quinteros S, Conomos MP, Deelman E, Do R, Doheny K, Fernández-Rhodes L, Fornage M, Hailu B, Heiss G, Henn BM, Hindorff LA, Jackson RD, Laurie CA, Laurie CC, Li Y, Lin DY, Moreno-Estrada A, Nadkarni G, Norman PJ, Pooler LC, Reiner AP, Romm J, Sabatti C, Sandoval K, Sheng X, Stahl EA, Stram DO, Thornton TA, Wassel CL, Wilkens LR, Winkler CA, Yoneyama S, Buyske S, Haiman CA, Kooperberg C, Le Marchand L, Loos RJ, Matise TC, North KE, Peters U, Kenny EE, Carlson CS31217584
John Ringman on Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
COMMENT Though we have made substantial progress in characterizing the behavior of biochemical and imaging biomarkers in presymptomatic and manifest Alzheimer’s disease, we still need an inexpensive and noninvasive index for the presence of AD pathology and its ...
David Knopman on Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
COMMENT This study involved persons with dominantly inherited Alzheimer disease mutations who donated plasma samples. The key finding was that ptau181 levels were elevated in both symptomatic and asymptomatic individuals and, in particular, modeling indicated ...
Suzanne Schindler on Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
COMMENT This paper provides further evidence that plasma ptau181 may be an excellent blood-based biomarker for Alzheimer disease brain pathology and symptomatic status. Interestingly, the investigators found very high intra-individual variation in p-tau181 levels ...
Oskar Hansson on Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
COMMENT The paper describes changes in plasma concentrations of P-tau181 in familial Alzheimer’s disease. The authors found that similar to plasma NfL, the P-tau181 concentrations started to increase around 15 years prior to symptom onset. The unadjusted ...
Jeffrey Dage on Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
COMMENT In this study of P-tau181 and NfL in plasma of familial Alzheimer’s disease, O’Connor et al. leverage an in-house-developed P-tau181 assay and commercial Quanterix NF-Light assay. This NfL assay is widely used. The P-tau181 assay, although new, is gaining ...